High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer

Por Suzman, Daniel L., Antonarakis, Emmanuel S.
Publicado em 2013

Castration-resistant prostate cancer: latest evidence and therapeutic implications

Por Suzman, Daniel L., Antonarakis, Emmanuel S.
Publicado em 2014

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer

Por Suzman, Daniel L., Antonarakis, Emmanuel S.
Publicado no Cancers (Basel) (2015)

Does Degree of Androgen Suppression Matter in Hormone-Sensitive Prostate Cancer?

Por Suzman, Daniel L., Antonarakis, Emmanuel S.
Publicado no J Clin Oncol (2015)

Determining the Optimal Treatment for Metastatic Castration-resistant Prostate Cancer: Age Should Not Be a Factor

Por Suzman, Daniel L., Eisenberger, Mario A.
Publicado em 2013

Bone-targeting agents in prostate cancer

Por Suzman, Daniel L., Boikos, Sosipatros A., Carducci, Michael A.
Publicado em 2014

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

Por Suzman, Daniel L., Luber, Brandon, Schweizer, Michael T., Nadal, Rosa, Antonarakis, Emmanuel S.
Publicado em 2014

Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with non-hormonal agents: Combined analysis of four phase-2 tr...

Por Suzman, Daniel L., Zhou, Xian C., Zahurak, Marianna L., Lin, Jianqing, Antonarakis, Emmanuel S.
Publicado no Prostate Cancer Prostatic Dis (2014)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Por Kazandjian, Dickran, Suzman, Daniel L., Blumenthal, Gideon, Mushti, Sirisha, He, Kun, Libeg, Meredith, Keegan, Patricia, Pazdur, Richard
Publicado no Oncologist (2016)

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma

Por Agrawal, Mridul, Kanakry, Jennifer, Arnold, Christina A., Suzman, Daniel L., Mathieu, Luckson, Kasamon, Yvette L., Gladstone, Douglas E., Ambinder, Richard F., Ghosh, Nilanjan
Publicado em 2014

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy

Por Ning, Yang‐Min, Suzman, Daniel, Maher, V. Ellen, Zhang, Lijun, Tang, Shenghui, Ricks, Tiffany, Palmby, Todd, Fu, Wentao, Liu, Qi, Goldberg, Kirsten B., Kim, Geoffrey, Pazdur, Richard
Publicado no Oncologist (2017)

Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer

Por Maughan, Benjamin L., Suzman, Daniel L., Luber, Brandon, Wang, Hao, Glavaris, Stephanie, Hughes, Robert, Sullivan, Rana, Harb, Rana, Boudadi, Karim, Paller, Channing, Eisenberger, Mario, Demarzo, Angelo, Ross, Ashely, Antonarakis, Emmanuel S.
Publicado no Cancer Chemother Pharmacol (2016)

Identification of Novel Markers for Liver Fibrosis in HIV/HCV Co-infected individuals using Genomics-based Approach

Por Suzman, Daniel L., McLaughlin, Mary, Hu, Zonghui, Kleiner, David E., Wood, Brad, Vailati, Mary, Lempicki, Richard A., Mican, JoAnn M., Suffredini, Anthony, Masur, Henry, Polis, Michael A., Kottilil, Shyam
Publicado em 2008

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

Por Boudadi, Karim, Suzman, Daniel L., Anagnostou, Valsamo, Fu, Wei, Luber, Brandon, Wang, Hao, Niknafs, Noushin, White, James R., Silberstein, John L., Sullivan, Rana, Dowling, Donna, Harb, Rana, Nirschl, Thomas R., Veeneman, Brendan A., Tomlins, Scott A., Wang, Yipeng, Jendrisak, Adam, Graf, Ryon P., Dittamore, Ryan, Carducci, Michael A., Eisenberger, Mario A., Haffner, Michael C., Meeker, Alan K., Eshleman, James R., Luo, Jun, Velculescu, Victor E., Drake, Charles G., Antonarakis, Emmanuel S.
Publicado no Oncotarget (2018)